Can some MS drugs protect and restore myelin in MS?

Associate Professor Anthony Don

Associate Professor Anthony Don

The Centenary Institute and the University of Sydney, NSW

| Better treatments | Immunology | Project | 2021 | Investigator Led Research |
SUPPORT PROJECTS WITH THIS RESEARCH FOCUS

Summary

In MS, the immune system mistakenly attacks the fatty substance covering nerve cells, called myelin. This triggers inflammation and loss of the protective coating around some nerves. To date, the drugs used to treat MS are mostly immunosuppressive in nature and we are yet to see an effective drug to repair this damage to myelin. There is an urgent need for new drugs to both protect myelin and to promote myelin growth and repair, termed remyelination.

There is a group of drugs used to treat MS called sphingosine-1-phosphate (S1P) receptor agonists, known more commonly as S1Ps, such as fingolimod (Gilenya), siponimod (Mayzent) and the newer addition, ozanimod (Zeposia). These drugs are known to be immunosuppressive in nature, reducing the inflammation commonly seen in MS. However, recent evidence suggests that they may in fact also have properties to promote remyelination. It is also thought that some people living with MS may have low levels of naturally occurring S1P in the body and that these drugs can act like the naturally occurring S1P, potentially explaining some of their positive effects.

Associate Professor Don and his team will investigate if the S1P drugs are myelin protective, if they promote the formation of myelin, and the processes by which this may happen. Additionally, the research team will also explore whether people living with MS may be deficient in the S1P in the first place, helping us to better understand how this class of drug impacts MS. This research will add to our understanding of the mechanisms of action for these drugs, as well as shedding light on a potential source of remyelination for those living with MS.

Updated 20 January 2021

Updated: 19 January, 2021

Stages of the research process

Fundamental laboratory
Research

Laboratory research that investigates scientific theories behind the possible causes, disease progression, ways to diagnose and better treat MS.

Lab to clinic timeline: 10+ years
Translational
Research

Research that builds on fundamental scientific research to develop new therapies, medical procedures or diagnostics and advances it closer to the clinic.

Lab to clinic timeline: 5+ years
Clinical Studies
and Clinical Trials

Clinical research is the culmination of fundamental and translational research turning those research discoveries into treatments and interventions for people with MS.

Lab to clinic timeline: 1-5 years

Grant Awarded

  • Project Grant

Total Funding

  • $115,900

Duration

  • 3 years

Contact Us

We're not around right now. But you can send us an email and we'll get back to you, asap.

Start typing and press Enter to search